Is Enveric Biosciences, Inc. (ENVB) a Buy, Sell, or Hold?
NASDAQ : ENVB
Enveric Biosciences, Inc.
$1.34 USD
-$0.02 (-1.47%)
- Volume
- 176.24K
- Average Volume
- 3.74M
- Market Capitalization
- $800K
- P/E Ratio
- -0.05
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $17.64
- Year Low
- $1.26
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $11.67
Company Overview
NASDAQ
Joseph Edward Tucker
Biotechnology
Healthcare
ENVB
6
US
USD
Liquidity Metrics
0.00
11.67
11.66
10.66
0.00
Sales & Valuation
-$
0.00
0.40
-0.10
-5.30
Profitability
-$36.24
-$12.13M
0.00%
0.00%
-220.99%
-148.88%
P/E Metrics
-0.05
0.00
0.00
Analyst Price Target & Rating
2/5
4 Analysts
%
Poll Results
About Enveric Biosciences, Inc. (NASDAQ:ENVB) Stock
Enveric Biosciences, Inc. is a pharmaceutical firm focused on advancing diverse cannabinoid-based medications, primarily for use in cancer care. The company's robust product pipeline includes EV104, developed for treating osteoarthritis, and EVM-101 and EVM-201, which are intended to alleviate cancer-related distress. Furthermore, EVM-301 is under development for a mental health indication, alongside EV102, a cannabinoid cream formulated for topical skin application. Rounding out their portfolio is EV101, a novel combination therapy integrating cannabinoids with chemotherapy. This innovative company is based in Naples, Florida. ...
Enveric Biosciences Announces Participation in B. Riley Securities Mind, Muscle & Vision Summit
2026-06-29 08:00:00
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced its participation in the B. Riley Securities Mind, Muscle & Vision Summit, being held on July 16, 2026, in Boston, MA. Joseph Tucker, Ph.D., CEO of Enveric, will participate in a Neuropsychiatry Fireside Chat to discuss current trends within t.
Enveric Biosciences Announces Participation in 2026 BIO International Convention
2026-06-16 10:01:00
Enveric Biosciences (NASDAQ: ENVB) (âEnvericâ or the âCompanyâ), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics t
Enveric Biosciences Announces Participation in 2026 BIO International Convention
2026-06-16 09:28:00
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced that the company is participating in the BIO International Convention being held June 22-25, 2026, in San Diego, California. “We are arriving at BIO with strong operational momentum, driven by the recently announced positive preclinical phototoxic.
Enveric Biosciences to Participate in the UBS 3rd Virtual CNS Day
2026-06-09 08:00:00
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced that the company is participating in the UBS 3rd Virtual CNS Day being held on June 15, 2026. During the virtual event, members of Enveric's management team will conduct one-on-one meetings with registered investors to discuss the company's busine.
2026-06-02 08:00:00
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced the Initiation of Investigational New Drug (IND)-enabling Genotoxicity studies of its lead candidate neuroplastogen, EB-003. The initiated Good Laboratory Practice (GLP) studies will evaluate the potential for the compound to interact with DNA and.
2026-05-19 08:00:00
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced promising results from preclinical in vitro experiments evaluating the risk for phototoxicity, which indicated no photoreactive potential for EB-003, further derisking its continued development for the chronic treatment of neuropsychiatric disorde.
Enveric Biosciences Reports Financial Results and Provides Corporate Update for First Quarter 2026
2026-05-15 09:00:00
Enveric Biosciences (NASDAQ: ENVB) (âEnvericâ or the âCompanyâ), a biotechnology company advancing next-generation neuroplastogenic small molecules to
Enveric Biosciences Reports Financial Results and Provides Corporate Update for First Quarter 2026
2026-05-15 08:00:00
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, today reported financial results for the first quarter ended March 31, 2026, and provided a comprehensive business update. CEO Commentary: “Our progress in the first quarter of 2026 reflects continued execution against our core mission of developing therapeutics ca.
Frequently Asked Questions
-
What is the current Enveric Biosciences, Inc. (ENVB) stock price?
-
Enveric Biosciences, Inc.(NASDAQ:ENVB) stock price is $1.34 in the last trading session. During the trading session, ENVB stock reached the peak price of $17.64 while $1.26 was the lowest point it dropped to. The percentage change in ENVB stock occurred in the recent session was --1.47% while the dollar amount for the price change in ENVB stock was -$0.02.
-
ENVB's industry and sector of operation?
-
The NASDAQ listed ENVB is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of ENVB?
-
Joseph Edward Tucker | Chief Executive Officer & Director
Peter J. Facchini | Chief Innovation Officer
Kevin Coveney | Chief Financial Officer
|
| -
How many employees does ENVB have?
-
Number of ENVB employees currently stands at 6. ENVB operates from 245 First Street, Cambridge, MA 34103, US.
-
Link for ENVB official website?
-
Official Website of ENVB is: https://www.enveric.com
-
How do I contact ENVB?
-
ENVB could be contacted at phone #239 302 1707 and can also be accessed through its website. ENVB operates from 245 First Street, Cambridge, MA 34103, US.
-
How many shares of ENVB are traded daily?
-
The average number of ENVB shares traded daily for last 3 months was 3.74M.
-
What is the market cap of ENVB currently?
-
The market value of ENVB currently stands at $800K with its latest stock price at $1.34